Introduction
Gene therapy is a medical approach with great promise, especially for genetic disorders and cancers, because it is difficult to develop chemical pharmacotherapies for genetic disorders. For gene therapy, the development of effective and safe nucleic acid delivery systems is required. Non-viral vectors are safer platforms than viral vectors because of lower immunogenicity and more reproducibility and because of easy processing and chemical modification. Among non-viral vectors, cationic liposomes can be safely prepared with biocompatibility and biodegradability (Huang et al., 2014) . Therefore, cationic liposomemediated transfection has great potential for clinical use.
Compared with viral vectors, transfection efficiency (TE) of cationic liposomes is low and clinically insufficient. One reason for this is reactive oxygen species (ROS) generation, which induces cytotoxicity (Yun et al., 2016) and affects intracellular signaling pathways (Mikhed et al., 2015) . It has been suggested that the cytotoxicity of cationic carriers, especially 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-based cationic liposomes, is caused by ROS generation. The high surface density of positive charges on cationic liposomes is critical for ROS generation . ROS are continuously generated by ROS producers and eliminated through ROS-scavenging systems to maintain redox homeostasis under physiological conditions. Upon disruption of the equilibrium, cell damage occurs (Glasauer and Chandel, 2014) . Moreover, ROS regulate cell differentiation, proliferation, migration, and apoptosis. In addition, they affect classical regulation of gene expression, including the stability of mRNAs and their transport in the cytosol (Adcock et al., 2004) .
Cationic liposomes loaded with nucleic acids enter tumor cells and release therapeutic genes mostly via endocytosis (Rejman et al., 2005) . During endocytosis, there are two possible sites that trigger ROS generation, namely where cationic liposomes interact with cytoplasmic and endosomal membranes . If nanoparticles are degraded in lysosomes, instead of transferring therapeutic genes to nuclei for gene transfection, ROS generation is also triggered . Although the amount of ROS generated by cationic liposomes is limited, they may trigger ROS production in mitochondria by the activity of NADPH (nicotinamide-adenine dinucleotide phosphate, reduced form) oxidase or lipoxygenase . Mitochondrial dysfunction caused by cationic liposomes has been shown previously (Roursgaard et al., 2016) , which also aggravates cellular damage. Such cytotoxicity has even been used for cancer therapy by cargo-free cationic liposomes (Yun et al., 2016) .
As a free radical scavenger and cytoprotective drug, edaravone has been widely used for neurological recovery following acute brain ischemia and subsequent cerebral infarction by reducing ROS and inhibiting apoptosis (Kikuchi et al., 2012) . Because the specific ROS generated by cationic liposomes are still unclear, a strategy to scavenge both hydrophilic and lipophilic ROS is reasonable. As an amphiphilic compound, edaravone has a similar ability as α-tocopherol for lipid hydroperoxide radical scavenging and with ascorbic acid for inhibiting hydro-soluble peroxide radicals (Abe et al., 2004) . Indeed, edaravone protects HT22 cells from H 2 O 2 -induced injury by inhibiting the production of ROS and activation of the mitogen-activated protein kinase signaling pathway (Zhao et al., 2013) . Moreover, edaravone protects osteoblastic cells/osteoblasts through its ROS-scavenging capacity by repressing dexamethasone-induced opening of mitochondrial permeability transition pores and reduction of the mitochondrial membrane potential (Sun et al., 2015) . We hypothesized that the anti-oxidative effects of edaravone might regulate oxidative stress during transfection to prevent cellular damage and improve TE.
In the present study, we investigated the effects of edaravone on cationic liposome-induced gene transfection. According to our results, the addition of free edaravone or edaravone-loaded liposomes (EDLPs) increased TE several fold in human hepatoma HepG2 cells and mice. This enhancement by edaravone was dose-dependent. Because ROS generation-mediated cellular damage cannot be avoided during cationic lipid-based gene transfection, edaravone may be useful to protect cells from harmful ROS, thereby enhancing transgene expression.
Materials and methods

Materials and reagents
DOTAP chloride was obtained from NOF Corporation (Tokyo, Japan). Edaravone was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). CellROX™ Deep Red was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Propidium iodide (PI) was obtained from Wako Pure Chemical Industries (Osaka, Japan). All organic solvents of analytical grade were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cholesterol and other inorganic chemicals were obtained from Nacalai Tesque (Kyoto, Japan). Purified water was prepared using a Direct-Q UV (Merck Millipore, Merck KGaA, Darmstadt, Germany). All cell culture media were purchased from Thermo Fisher Scientific.
Preparation of plasmid DNA (pDNA)
Amplification of pDNAs pCpGfree-lucia (InvivoGen, CA, USA), pZsGreen1-N1 (Clontech, Shiga, Japan) and pCMV-luciferase [constructed previously (Fumoto et al., 2016) ], was performed using Escherichia coli strains GT115, DH5α and DH5α, respectively. Isolation and purification were carried out using an EndoFree® Plasmid Giga Kit (QIAGEN GmbH, Hilden, Germany). Purified pDNA was dissolved in 5% glucose and stored at −20°C.
Preparation of cationic liposomes and EDLPs
The calcium acetate gradient method (Hironaka et al., 2011) was chosen to prepare EDLPs because edaravone is partially hydro-soluble. Cationic liposomes consisting of DOTAP and cholesterol (8:1 M ratio) were prepared by a thin lipid film hydration method with 120 mM calcium acetate to produce a 16 mg/ml lipid dispersion using a vortex mixer. After hydration, submicron-sized liposomes were prepared using a commercially available instrument (Mini-Extruder; Avanti Polar Lipids, Inc., AL, USA) with a size-controlled polycarbonate membrane (0.1 μm pore size). The liposomes were dialyzed in Hank's balanced salt solution with 0.01 M 2-morpholinoethanesulfonic acid (pH 6.0) at 4°C to create a gradient. Some of the liposomes were used as plain cationic liposomes. Remote loading was performed by co-incubation with edaravone solution to prepare EDLPs at 37°C for 10 min.
Characterization of EDLPs
To determine the encapsulation efficiency (EE) of edaravone in EDLPs, free edaravone was separated by centrifugal ultrafiltration at 5000×g for 25 min at 4°C (molecular weight cut-off: 10,000; Merck Millipore). To measure the total amount of edaravone, 50 μl of the EDLP dispersion was added to 5 ml mobile phase, sonicated for 5 min, and then centrifuged at 12,000×g for 10 min before analysis. According to Japan Pharmacopeia (JP17), the edaravone content was analyzed by high performance liquid chromatography with a UV detector (SPD-10A, Shimadzu, Kyoto, Japan) under the following conditions: C18 column (Cosmosil-Pak; 4.6 × 150 mm; particle diameter: 5 μm) with methanol, water, and acetic acid (100:100:1) as the mobile phase, at a wavelength of 240 nm and 25°C. The total run time was 15 min. The EE of EDLPs was calculated by the following equation:
total free total where E total is the total edaravone amount in EDLPs and E free is the free edaravone amount in the EDLP dispersion.
Preparation of lipoplexes
The lipoplexes were prepared with equal volumes of pDNA and cationic liposomes, then incubated at 37°C for 30 min with a charge ratio (molar ratio of cationic lipids to pDNA phosphate residues) of 3.5. For in vitro experiments, we used pCpGfree-lucia encoding the secretable form of the synthetic luciferase gene. For in vivo experiments, pCMV-luciferase encoding the non-secretable form of the firefly luciferase gene was chosen. The particle size and ζ potential of liposomes and lipoplexes at 25°C were measured using a Zetasizer Nano ZS (Malvern, Worcestershire, UK).
Cell culture
HepG2 cells were obtained from RIKEN (Tokyo, Japan). The cells were grown under standard conditions in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin G (100 U)/streptomycin (100 µg/ml) in a humidified atmosphere with 5% CO 2 at 37°C.
In vitro TE measurement
HepG2 cells were seeded into 24-well plates at a density of 4 × 10 4 cells/cm 2 in 0.5 ml medium and cultured for 24 h. The medium was replaced with FBS-free DMEM containing edaravone, EDLPs, or H 2 O 2 with lipoplexes (1 μg/well pCpGfree-lucia). After transfection for 4 h, the cells were washed with phosphate buffered saline (PBS; pH 7.4) and then incubated with 10% FBS/DMEM at 37°C for another 4 h. TE in cells was assessed by mixing 5 μl medium with 100 μl substrate (Renilla Luciferase Assay System containing luciferase substrate coelenterazine; Promega, USA) and immediate measurement of the bioluminescence level by a luminometer (Lumat LB 9507; Berthold Technologies, Bad Wildbad, Germany). Luciferase activity is indicated as relative light units (RLU)/ml of medium.
Flow cytometric analysis
HepG2 cells were seeded into 24-well plates at a density of 4 × 10 4 cells/cm 2 in 0.5 ml medium and cultured for 24 h. The medium was replaced with FBS-free DMEM containing lipoplexes at 1 μg/well pZsGreen1-N1 with or without edaravone (100 μM). After transfection for 4 h, the cells were incubated with CellROX™ Deep Red for 30 min according to the manufacturer's protocol. The cells were washed with PBS three times and then incubated with 10% FBS/DMEM at 37°C for another 12 h. The cells were harvested and centrifuged at 1500×g for 5 min at 4°C. After washing twice with PBS containing 5% FBS, cells were re-suspended in the same solution and analyzed by flow cytometry (LSRFortessa X-20, BD Biosciences, CA, USA).
Gene transfection by polyethyleneimine (PEI) and lipofectamine® 3000
Similar to the conditions for cationic liposomes, HepG2 cells were seeded into 24-well plates at a density of 4 × 10 4 cells/cm 2 in 0.5 ml medium and pre-incubated for 24 h. Medium containing 1 μg/well pCpGfree-lucia/PEI polyplexes (PEI HCl MAX, linear, molecular weight 40 k (22 k in free base), Polysciences, Inc., PA, USA) with an N/P ratio (the ratio of moles of the amine groups of PEI to those of the phosphate groups of pDNA) of 10 with or without free edaravone was incubated for 4 h, and then washed and transferred to normal DMEM and incubated for another 4 h. The process for Lipofectamine® 3000 (Thermo Fisher Scientific)-mediated transfection was similar to that for PEI and followed the manufacturer's protocol. TE in cells was assessed by mixing the medium and substrates as described above, and then measuring the bioluminescence level using a luminometer (Lumat LB 9507; Berthold Technologies). Luciferase activity is also indicated as RLU/ml of medium.
Cell metabolic activity, cell death, and TE
For evaluation of cell metabolic activity, cells were seeded in 96-well plates at a density of 3.6 × 10 4 cells/cm 2 and pre-incubated for 24 h. Free edaravone or lipoplexes with or without 100 μM edaravone were added to the wells, followed by incubation for 4 h. After incubation for a further 4 h in drug-free DMEM, the medium was collected for TE measurement. TE was measured as described in Section 2.7. After collection of medium, each well was washed with PBS, then 100 µl DMEM containing 10 µl of cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was added and the cells incubated for 1 h. The absorbance was measured at 450 nm using a microplate photometer (Multiskan™ FC; Thermo Fisher Scientific). Blank wells and untreated cells served as negative and positive controls, respectively. For cell death measurement, HepG2 cells were seeded into 24-well plates at a density of 4 × 10 4 cells/cm 2 in 0.5 ml medium and cultured for 24 h. Medium containing lipoplexes at different lipid concentrations with or without 100 μM edaravone was added to the wells, followed by incubation for 4 h. The cells were washed with PBS, and then incubated with 10% FBS/DMEM at 37°C for another 4 h. Cells were harvested and centrifuged at 1500×g for 5 min at 4°C. Then, cells were washed twice and re-suspended in 5% FBS in PBS. After incubation with PI (0.5 μg/ ml) for 5 min at room temperature, the cells were analyzed using a Tali™ Image-Based Cytometer (Thermo Fisher Scientific).
Animals
Five-week-old male ddY mice (Japan SLC, Inc., Shizuoka, Japan) weighing 25-27 g were used in experiments and fed a standard laboratory diet in air-conditioned chambers at a constant temperature and humidity. All experiments were approved by the Institutional Animal Care and Use Committee of Nagasaki University.
In vivo gene transfer
To measure in vivo TE, lipoplexes with various edaravone dosages were administered via the tail vein of mice. Ninety micrograms of pCMV-luciferase in 150 µl of a 5% glucose solution was mixed with the same volume of cationic liposomes and incubated at 37°C for 30 min with a charge ratio of 3.5. Then, 25 µl of the various dosages of EDLPs (8 µg/µl) was added and mixed well. Administration of the complexes was carried out through the tail vein. The measurements were finished after 6 h, followed by immediate euthanasia of the animals. Lungs and livers were dissected, washed with saline, and then homogenized on ice after adding 4 µl/mg tissue lysis buffer (0.1 M Tris-HCl, pH 7.8, 0.05% Triton X-100, 2 mM EDTA) (Fumoto et al., 2016) . After the homogenates were centrifuged at 15,000 ×g for 5 min at 4°C, 20 μl of tissue homogenate supernatant was mixed with 100 µl luciferase assay substrate (PicaGene®, Toyo Ink Mfg. Co., Ltd., Tokyo, Japan). The light produced was measured using a luminometer (Lumat LB 9507; Berthold Technologies). The luciferase activity is represented as RLU/g of tissue.
Measurement of serum transaminase activities
Blood was collected from mice 24 h after intravenous injection of 5% glucose, lipoplexes, lipoplexes with 600 µg free edaravone, or EDLPs containing 30 µg edaravone. After the blood had clotted, samples were centrifuged at 15,000×g for 5 min and the supernatants were collected to obtain serum. Serum AST and ALT activities were measured with a transaminase C II test kit (Wako Pure Chemical Industries).
Statistical analysis
Statistical comparisons were performed using Student's unpaired ttest for comparisons of two groups, and one-way analysis of variance followed by Dunnett's post hoc test for multiple comparisons with a control group or Tukey's post hoc test for multiple comparisons among different groups. Values of P < 0.05 were considered to indicate statistical significance.
Results
Preparation and characterization of EDLPs
The ultimate goal of the present study was in vivo transfection. Therefore, we first formulated EDLPs. To trap edaravone in liposomes by remote loading, we decreased the cholesterol proportion relative to DOTAP from a DOTAP:cholesterol ratio of 1:1 to enhance the EE of EDLPs. The molar ratio of DOTAP to cholesterol was optimized after single factor assessments of EE, particle size, and the polydispersity index (PDI). The particle size and PDI of EDLPs before and after incubation were almost unchanged (data not shown). A molar ratio of DOTAP:cholesterol of 8:1 was selected as the optimal formulation. The highest EE of approximately 67% after incubation for 10 min at 37°C was obtained at a certain concentration of edaravone by the calcium acetate gradient method. The final edaravone concentration was 2 mg/ ml. Before and after dialysis, the size, PDI, and ζ potential of liposomes were maintained at around 100 nm, 0.07, and 84 mV, respectively. After incubation with pDNA, the size doubled (209.7 ± 0.7 nm), while the ζ potential halved (45.5 ± 1.0 mV) with an increase in PDI (0.240 ± 0.003).
In vitro TE by free edaravone and EDLPs
As shown in Fig. 1A , 100 μM edaravone had the strongest ability to promote TE (6.1 times higher) compared with the control group. This efficiency was highly dependent on the applied dose of edaravone. Below 100 μM, the TEs were slightly increased from the control group but less effective than 100 μM. When the edaravone concentration was more than 250 μM, the TE tended to decrease with increasing concentration, especially at 1000 μM. After liposome formation, EDLPs containing only 2 μM edaravone showed highly improved TE (7-fold) compared with the control group (Fig. 1B) . The relationship between the edaravone concentration and TE was bell-shaped.
Relationship between TE and ROS levels in cells
We analyzed the relationship between TE and cellular ROS levels by flow cytometry. The number of gene expression-positive cells was increased by co-incubation with 100 μM edaravone (Fig. 2B ) compared with the control group ( Fig. 2A ) with a significant difference in mean fluorescence intensity (Fig. 2D ). Lipoplexes enhanced cell ROS levels in comparison with the basal level ( Fig. 2A, C and E) . The cell ROS level was decreased by the addition of edaravone ( Fig. 2A, B and E) . As expected, the gene expression-positive cells in the control and edaravone groups were both centralized in the ROS-negative quadrant ( Fig. 2A  and B) .
TE in a gradient H 2 O 2 environment
To assess the effect of ROS on TE, we added H 2 O 2 . As shown in Fig. 3 , TE decreased with increasing concentration of H 2 O 2 and was sharply reduced at 1000 μM in the absence of edaravone. Edaravone effectively enhanced TE at all cellular ROS levels, and this enhancement was very high when the H 2 O 2 concentration was more than 250 μM. These results are in line with those in Fig. 1A; i.e. suppression of ROS increased TE.
Dependency of cell metabolic activity, cell death, and TE on edaravone concentration
To check the effects of edaravone itself on HepG2 cells, we . pCpGfree-lucia (2 μg/ml, 1 μg/well) was complexed with cationic liposomes at a charge ratio of 3.5. Free edaravone (A) or EDLPs (B) at various concentrations were mixed with lipoplexes and then transfected for 4 h. The lipid content for all groups was equalized by plain cationic liposomes (B). Luciferase activity in the medium was determined after incubation for a further 4 h. Each bar represents the mean + SD (n = 3). ** P < 0.01, compared with the control. (Fig. 4A) . Approximately 100% cell metabolic activity was observed with edaravone at less than 500 μM. Even at 1000 μM edaravone, the metabolic activity of HepG2 cells was still > 90%. However, the cytotoxicity of cationic lipoplexes was obvious in terms of cell metabolic activity (Fig. 4B) . The CCK-8 assay showed a lipid concentration-dependent decrease in HepG2 cell metabolic activity, especially at concentrations of > 50 μM (Fig. 4B) . In Figs. 1-3 , the lipid concentration was 23.4 μM. At concentrations of 20 and 50 μM, the lipoplexes without edaravone showed slight inhibition of cell metabolic activity, indicating partial toxicity. Edaravone rescued the cells with partial toxicity. Dehydrogenase-based assays, such as the CCK-8 assay, reflect cell conditions that depend on several elements including NAD (H), NADP(H), and mitochondrial activity. Because cellular ROS levels might affect the CCK-8 assay results, we also measured cell death using PI (Fig. 4C) . Cell death was low below 10 μM. Increasing lipid concentration resulted in increased cell death. Again, edaravone rescued the cells from death at moderate lipid concentrations between 20 and 50 μM. TE reached a plateau at a lipid concentration of 50 μM, at which edaravone significantly enhanced the TE (Fig. 4D) . At a lipid concentration of 100 μM, cell death was obvious with or without edaravone (Fig. 4C) , and there was no significant difference in TE (Fig. 4D) . The concentration of edaravone (100 μM) might be insufficient at such high lipid concentration.
Effect of edaravone on transfection mediated by PEI and lipofectamine® 3000
Because edaravone had a promising effect on the DOTAP-based nonviral transfection system, we applied edaravone to other non-viral vectors. Edaravone had a significant effect on Lipofectamine® 3000 transfection (Fig. 5A) . Compared with normal conditions, the TE of Lipofectamine® 3000 was enhanced by more than > 3-fold by co-incubation with 250 μM edaravone. As a cationic lipid-based transfection system, the relationship between TE and edaravone concentration was almost identical to the former results (Fig. 1) . Unfortunately, ROS scavenging by edaravone scarcely improved TE of linear PEI polyplexes Fig. 3 . Effect of H 2 O 2 co-incubation on TE with or without edaravone. pCpGfree-lucia (2 μg/ml, 1 μg/well) was complexed with liposomes at a charge ratio of 3.5. Various amounts of H 2 O 2 (0-1000 μM) with or without 100 μM edaravone were mixed with lipoplexes and then transfected into HepG2 cells for 4 h. Luciferase activity in the medium was determined after incubation for an additional 4 h. Each point represents the mean + SD (n = 3). * P < 0.05, compared with the control. with a maximum 1.6-fold increase compared with the control at 100 μM and even produced decreased TE at edaravone concentrations higher than 250 μM (Fig. 5B) .
In vivo TE
EDLPs effectively increased TE at certain doses, especially in the 30 μg group, which demonstrated 20 times higher TE than the control group in the lungs (Fig. 6A) . Such enhancement also occurred in the liver (Fig. 6B ). Concerning the difference in the doses giving the highest TE between the lungs (30 μg) and liver (40 μg), the amount of EDLPs containing 40 μg edaravone in the lungs may have been saturated, providing more edaravone for the liver than the 30 μg dose to scavenge ROS. Similar to the in vitro conditions, the dose-dependency of edaravone was also observed to be bell-shaped in mice. Furthermore, pulmonary TE was several times higher than hepatic TE in all mice because cationic liposomes were mainly trapped in the lungs. Free edaravone solution with a similar dose (30 μg) did not increase TE in either organ ( Fig. 6C and D) . Increasing the dose of free edaravone to 270 μg and 600 μg slightly improved TE in the lungs. For the liver, only 270 μg increased TE efficiency, indicating that 600 μg of edaravone might be an overdose as it produced no TE enhancement. Fig. 5 . Effect of edaravone on TE mediated by Lipofectamine® 3000 (A) and PEI (B) complexes. pCpGfree-lucia (2 μg/ml, 1 μg/well) was complexed with PEI at an N/ P ratio of 10, whereas lipoplexes containing Lipofectamine® 3000 were prepared following the manufacturer's protocol (1 μg/ml pCpGfree-lusia, 0.5 μg/well). Free edaravone at various concentrations was mixed with lipoplexes (A) or polyplexes (B), and then transfected into HepG2 cells for 4 h. Luciferase activity in the medium was determined after incubation for a further 4 h. Each bar represents the mean + SD (n = 3).
* P < 0.05, compared with the control.
Fig. 6. TE of lipoplexes in murine lungs (A, C) and livers (B, D) with various EDLP doses (A, B) and free edaravone (C, D)
. pCMV-luciferase (90 μg) was complexed with liposomes at a charge ratio of 3.5. Various doses of EDLPs and free edaravone were post-mixed with lipoplexes. The lipid content for all groups was equalized by plain cationic liposomes. Luciferase activity was determined at 6 h after administration. Each bar represents the mean + SD (n = 3). * P < 0.05, compared with the control.
The effect of edaravone on cationic lipoplex-induced hepatic toxicity
To assess the cytoprotective effects of edaravone in vivo, we measured serum AST and ALT levels as markers of hepatic toxicity. Serum AST and ALT levels in the vehicle group were 35.5 ± 9.3 and 18.0 ± 8.2 IU/L, respectively. These levels were greatly increased 24 h after lipoplex injection compared with the vehicle group (Fig. 7) . This indicated that the lipoplex treatment induced acute hepatic injury. The addition of free edaravone or EDLPs effectively decreased the serum transaminase activity levels. EDLPs with only 30 μg edaravone protected against acute hepatic toxicity to a similar degree as 600 μg free edaravone.
Discussion
The positive charge of carriers in non-viral transfection is a doubleedged sword. It promotes cellular uptake and endosome escape for gene transfer, but generates harmful ROS during membrane fusion in these processes . Several strategies can decrease ROS production and increase TE. For example, acetylation of branched PEI reduces ROS production (Calarco et al., 2013) , L-carnosine (antioxidant) (Dey et al., 2011) and α-lipoic acid (Dharmalingam et al., 2017) conjugations eliminate ROS produced by cationic materials. In this study, direct use of an antioxidant, rather than synthetic modification, simplifies the system and we show that the antioxidant, edaravone, improves cationic lipid-mediated transfection in HepG2 cells (Figs. 1, 2, 4 and 5) and mice (Fig. 6) .
To choose the best anti-oxidant for TE enhancement, we tested six antioxidants, i.e., edaravone, all-trans retinoic acid (ATRA), α-tocopherol, ascorbic acid, N-acetylcysteine (NAC) and N-tert-butyl-α-phenylnitrone (PBN) (Fig. 1A and Supplementary Fig. S1 ). Edaravone produced the strongest enhancement of TE among the tested anti-oxidants. Partition coefficient (LogP) is critical for cellular uptake and intracellular disposition. Edaravone, an amphiphilic compound with a moderate LogP value (Supplementary Table S1 ), has a similar ability as α-tocopherol to inhibit lipid peroxide radicals and a similar ability as ascorbic acid to inhibit hydro-soluble peroxide radicals (Abe et al., 2004) . Although PBN has a similar LogP value (Supplementary Table  S1 ) and a similar TE-enhancing ability as edaravone (Fig. 1A and Supplementary Fig. S1 ), edaravone is effective at much lower concentrations than PBN. Overall, we consider that edaravone was more suitable to scavenge free radicals during transfection with lipoplexes than other anti-oxidants. We, therefore, chose edaravone for further experiments.
The concentration of edaravone was critical for TE enhancement (Fig. 1) . Considering the balance of ROS levels between cellular health and damage caused by ROS generation during gene transfection, moderate reduction of ROS levels by edaravone was efficacious, as shown in Fig. 1A . Edaravone effectively decreased cellular ROS levels, which was highly enhanced by lipoplexes (Fig. 2) . In addition, the population of gene expression-positive cells was significantly increased in the edaravone group (Fig. 2A, B and D) . It is clear that the gene expression-positive cells of both control and edaravone groups were centralized in the ROS negative quadrant by flow cytometry ( Fig. 2A  and B) . Furthermore, the percentage of cells with high ROS levels and without gene expression was decreased by edaravone, while the percentages of double negative and double positive quadrants were almost unchanged ( Fig. 2A and B) . These findings indicate that ROS generation during transfection was harmful for gene expression. Thus, the TE enhancement by edaravone was possibly attributed to scavenging of the ROS generated during transfection. However, when edaravone content was more than 250 μM there was a decrease in TE, possibly because the antioxidant capacity may reduce ROS to an extremely low level (Fig. 1A) . This inverse correlation between higher concentrations of edaravone content and TE might be attributed to extreme ROS reduction that worsens the health of HepG2 cells. It has been reported that ROS reduction by antioxidant MCI-186 (edaravone) results in cell cycle arrest without a decrease in viability (Suzuki et al., 2005) . In cell cycle arrest, nuclear membranes are generally intact with low permeability, thereby inhibiting transfection. Hence, retention of the cell redox balance maintains the status and condition of cells, which affects the TE.
As mentioned above, the TE enhancement by EDLPs (Fig. 1B) was also possibly attributed to the scavenging of generated ROS. EDLPs increased TE with a much lower content of edaravone ( Fig. 1A and B) . Therefore, modulation of ROS levels in the microenvironment by EDLPs might be better than that in the macroenvironment by free edaravone. Because free drug can be easily metabolized and distributed to nontargeted organs, the formation of EDLPs is preferable for in vivo delivery. Although EDLPs could increase TE more than seven times with much lower content, the adoption of EDLPs, i.e. edaravone-loaded cationic liposomes decreased the overall TE (Fig. 1A and B) . The relationship between charge ratio (CR) and gene transfection efficiency has been described as peak shaped, with an increase followed by a decrease (Elisabete et al., 2004) . In our experiment, the optimized charge ratio (3.5) was located on the anti-correlation side of the peak value (data not shown), which explains why TE was decreased by the addition of cationic lipids.
Similar to in vitro conditions, the TE enhancement in mice was also dose-dependent; TE increased and then decreased with the increase in edaravone dose (Fig. 6A and B) . The TE decrease at higher edaravone doses was possibly caused by interruption of redox homeostasis, which induced an extreme reduction in ROS (Glasauer and Chandel, 2014) . Maintenance of the redox equilibrium may be important for edaravonemediated enhancement of in vivo TE. In addition, the ROS generation by cationic liposomes not only disrupted the redox equilibrium to induce toxicity but also transmitted stress signals to the immune system. Accumulation of cationic lipoplexes can cause lung toxicity expressed as pulmonary inflammation. Such responses induced by cationic liposomes and lipoplexes have been observed and characterized by significant enhancement of several proinflammatory cytokines (Xue et al., 2014) . To overcome the inflammatory toxicity of cationic liposomemediated gene transfer, the sequential injection method (Tan et al., 2001 ) and modified cationic lipids (Elouahabi et al., 2003) have been developed. The inhibition of inflammatory responses by these strategies significantly enhance in vivo TE. ROS play a central role in inflammasome activation (Harijith et al., 2014) , and the scavenging of ROS by edaravone might restrain subsequent immunogenic responses. Systemic Fig. 7 . Effect of free edaravone and EDLPs on cationic lipoplex-induced hepatic toxicity. pCMV-luciferase (90 μg/mouse) was complexed with liposomes at a charge ratio of 3.5. Lipoplexes were mixed with EDLPs (30 μg edaravone) or free edaravone (600 μg). The lipid content for all groups was equalized by plain cationic liposomes. Serum transaminase activities, AST (empty bar) and ALT (filled bar), were determined 24 h after administration. Each bar represents the mean + SD (n ≥ 3). * P < 0.05, ** P < 0.01 compared among groups. ## P < 0.01 compared with other groups.
toxicities of lipoplexes by generating ROS include hepatic injury with elevated levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Xue et al., 2014) . In this study, edaravone and EDLPs ameliorated the acute hepatic injury caused by lipoplexes (Fig. 7) . This effect of edaravone might be attributed to its ability to directly scavenge for hydroxyl radicals (Zong et al., 2014) . Hence, the reduction of inflammation induced by cationic lipoplexes may be another factor that contributes to enhanced TE by edaravone administration in vivo.
It is noteworthy that free edaravone barely improved TE in mice at the same dosage with EDLPs (Fig. 6) . The lipoplexes and EDLPs may have formed a complex by electrostatic interactions with negatively charged blood proteins after intravenous injection. Five minutes after intravenous administration of EDLPs, nearly 70% of edaravone accumulated in the lungs (Supplementary Fig. S2 ). In contrast, free edaravone injection resulted in undetectable accumulation in the lungs. Accumulation of edaravone in the liver of free and EDLPs groups was comparable. Obviously, the biodistribution properties of edaravone in EDLPs was similar to those of liposomes, which were completely different from those of the free drug. ROS generation may be dependent on the accumulated amount of cationic lipoplexes. Free edaravone, unlike EDLPs, could not efficiently accumulate in organs. Therefore, a much higher dose of free edaravone is necessary to achieve TE enhancement (Fig. 6 ). EDLPs could achieve the synchronous distribution of edaravone and lipoplexes, and decrease the application dose of edaravone. Moreover, EDLPs (with only 30 μg of edaravone) could decrease serum AST and ALT levels as effectively as 600 μg of free edaravone (Fig. 7) . There is another possibility that co-delivery of lipoplexes and edaravone by the same endocytosis pathways may enhance the influence of edaravone. Edaravone would be released from EDLPs at the time of membrane fusion when ROS generation may occur, followed by rapid and direct ROS scavenging.
We measured the cytotoxicity of lipoplexes with or without edaravone (Fig. 4) and established an unbalanced ROS environment model (Fig. 3) . Transfection with the cationic liposomes resulted in high cell death rates at liposome concentrations of > 50 μM (Fig. 4C) . These results support findings from another study that showed cytotoxicity to be one of the most significant disadvantages of cationic-based transfections . The cellular protection by edaravone via removal of generated ROS may be critical for higher cell viability ( Fig. 4B and C) . The cytotoxicity of cationic liposomes can be separated into internalization (uptake)-dependent and -independent toxicities (Soenen et al., 2009 ). In addition, ROS generation is lipid-dose-dependent and then reaches a steady state level at concentrations higher than approximately 50-100 μM (Yun et al., 2016) . Thus, in large amounts, cationic liposomes cause extreme destabilization of the plasma membrane and cell collapse, partly explaining the inefficiency of edaravone with high lipid content (100 μM) (Fig. 4B, C and D) . To investigate oxidative stress responses of cells and cytoprotective effects of antioxidant agents, cells are usually exposed to H 2 O 2 in the culture medium. We tested the effect of an H 2 O 2 concentration gradient on TE enhancement by edaravone (Fig. 3) . Mammalian cell lines enter temporal growth arrest at > 100 μM H 2 O 2 and permanent growth arrest at > 250 μM (Gulden et al., 2010) . When the concentration is higher than 1000 μM, it results in necrotic cell death (Gulden et al., 2010) . Edaravone enhanced TE at all H 2 O 2 concentrations, possibly because of its capacity of ROS scavenging. These results strongly indicate the effectiveness of edaravone for TE enhancement.
Results using commercial products (Fig. 5 ) further proved our hypothesis that anti-oxidative effects of edaravone affect lipoplex-mediated transfection (lipofection). As a cationic lipid-based transfection agent, Lipofectamine® 3000 also generates ROS during endocytosis and membrane fusion, which explained TE enhancement at certain concentrations of edaravone (Fig. 5A) . However, edaravone inefficiently improved the gene expression level for PEI polyplexes (Fig. 5B) . Linear PEI polyplex-based transfection is induced by the 'proton sponge' effect with barely any ROS generation even at a high concentration (Hall et al., 2015; Nguyen and Szoka, 2012; Roursgaard et al., 2016) . The cytotoxicity of polyplexes is usually caused by undegradable material instead of sharply increased ROS generation and membrane instability induced by cationic lipids (Roursgaard et al., 2016) . In this case, edaravone might be inefficient at preventing PEI-induced cytotoxicity. Although edaravone may only work for lipofection, it would be able to enhance TE with high safety because edaravone itself is already used clinically.
Conclusion
This study demonstrated that edaravone increased TE by scavenging for superfluous ROS induced by cationic liposomes. To overcome the cytotoxicity of cationic liposomes, edaravone might eliminate the ROS generated during lipofection, which cause cellular damage. It was noteworthy that formation of EDLPs decreased the efficacious edaravone dose, especially in mice. Because ROS levels are associated with TE, modulation of cellular ROS is important for gene delivery.
